South Ko­re­an bio­phar­ma sees way for­ward af­ter PhI­II eye dis­ease tri­al fail­ure

HanAll Bio­Phar­ma’s dry eye drug failed to meet ei­ther of the pri­ma­ry end­points in a Phase III clin­i­cal tri­al, but the com­pa­ny said it still plans to pur­sue de­vel­op­ment of the drug.

HanAll re­port­ed the Phase III fail­ure on Fri­day, say­ing that the VE­LOS-3 tri­al test­ing a 0.25% so­lu­tion of tan­fan­er­cept in 260 pa­tients in the US with dry eye dis­ease failed to meet ei­ther of the two pri­ma­ry end­points: im­prove­ment from base­line in a corneal stain­ing score, and im­prove­ment — again from base­line — in an eye dry­ness score af­ter eight weeks, com­pared to a ve­hi­cle arm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER